Skip to content

Scientific validation

SPUR™ is already used on over 50,000 patients in 27 therapeutic areas (e.g., asthma, hypertension, breast cancer, multiple sclerosis, Type 2 diabetes). Seven scientific publications have validated that it delivers three helpful outputs for healthcare providers.

The SPUR behavioral model - Theoritical framework

A 3-Phase research plan 

We long wondered why a patient would not adhere to treatments that could benefit them the most, but couldn’t find the right tool for answering the question.

Determined to find answers, in 2017, we began the research and development that eventually produced SPUR™.

  • Phase 0 established our model’s academic foundations through a literature review, a board review, and the elaboration of a decision-making framework.

  • Phase 1 had two objectives: identifying the questions to be included in SPUR™ and evaluating the questionnaire’s psychometric properties. We conducted a literature review, a board review, and qualitative interviews with patients with diabetes, COPD, breast cancer, and multiple sclerosis.
  • Phase 2’s goals were to validate the SPUR tool’s final structure and predictive power with real-life adherence data through MPR via a multi-country quantitative analysis of Type 2 diabetes and a multi-pathology approach.

Seven scientific publications (in such journals as Patient Preference and Adherence, the British Medical Journal, and Current Medical Research and Opinion) have validated the predictive power of SPUR™.

Presenters at different European conferences, including the Health Services Research and Pharmacy Practice conference, and those of the International Society for Medication Adherence (ESPACOMP), the Institute of Molecular and Cellular Biology (IBMC), and the European Association for the Study of Diabetes, have also discussed SPUR™.